NeurosciencebioRxivPreprint
Brain-specific PP1/LRRK2 interaction-targeting peptides as a novel strategy for Parkinson's disease treatment
Séverine Loisel, Fanny Petit, Gwenaëlle Aurégan…·Angelita Rebollo
The paper develops a peptide, PEP 3, that disrupts the LRRK2/PP1 interaction and shows promise as a therapeutic for Parkinson's disease by reducing dopaminergic cell death and alpha-synuclein phosphorylation.
DOI 10.64898/2026.07.27.740889